Global Cell and Gene Therapy Market Report 2024: Growth Rate, Major Segments And Regions

The Cell and Gene Therapy by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Cell and Gene Therapy Market:
https://www.thebusinessresearchcompany.com/report/cell-and-genes-therapy-global-market-report

According to The Business Research Company’s Cell and Gene Therapy, The cell & gene therapy market size has grown exponentially in recent years. It will grow from $13.81 billion in 2023 to $17.31 billion in 2024 at a compound annual growth rate (CAGR) of 25.3%.  The  growth in the historic period can be attributed to increase in investments in cell and gene therapies, growth in research and development, advances in cancer drug discovery, rise in public-private partnerships, strong economic growth in emerging markets, increased healthcare expenditure, and rising in pharmaceutical r&d expenditure.

The cell & gene therapy market size is expected to see exponential growth in the next few years. It will grow to $39.74 billion in 2028 at a compound annual growth rate (CAGR) of 23.1%.  The growth in the forecast period can be attributed to increasing prevalence of cancer and chronic diseases, rising geriatric population, rising geriatric population, rising focus on cell and gene therapy, and rise in healthcare expenditure . Major trends in the forecast period include focusing on advanced therapies such as chimeric antigen receptor (car) t-cell therapy, concentrating on undertaking various research initiatives and attain funding, carrying out strategic collaborations to integrate advanced technologies, concentrating on developing gene/genome editing tools especially crispr, partnering or acquiring competitor companies, increasing the number of pipeline studies to develop cell and gene therapies, and investing in manufacturing facilities expansion.

Steady investment and consolidation in cell and gene therapies contributed to the growth of the cell and gene therapy (CGT) market. After recognizing the potential of the CGT market, 16 out of the 20 largest biopharmaceutical companies by revenue, added CGT products to their portfolios. For instance, in December 2021, Pfizer has invested $68.5 million in a new state-of-the-art facility in Durham, North Carolina, to further advance gene therapy capabilities. The facility expands Pfizer’s end-to-end capabilities in gene therapy and builds on the company’s existing footprint in North Carolina, which includes more than 3,600 employees across sites in the state.  Steady investment and consolidation in CGT production capacity led to an increase in production capacity and also contributed to the growth of the market.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=3472&type=smp

The cell and gene therapy market covered in this report is segmented –
1) By Product: Cell Therapy, Gene Therapy
2) By Application: Oncology, Neurological Disorders, Other Applications
3) By End User: Hospitals, Ambulatory Surgical Centers, Cancer Care Centers, Wound Care Centers, Other End-Users

Chimeric antigen receptor (CAR) T-cell therapy is shaping the cell and gene therapy (CGT) market. (CAR) T-cell therapy is a combination of cell and gene therapy in which T cells are collected from the patient’s blood and are genetically engineered to produce modified receptors at their surface, known as chimeric antigen receptors (CARs). These modified T cells have special structures (receptors) and are reinfused into the patient. Then, the modified receptors of T cells help in targeting the surface antigen of the cancer cell, ultimately resulting in the killing of tumor cells in patients. For instance, in June 2022, Bristol-Myers Squibb Company, a US-based pharmaceutical company, received approval from the United States Food and Drug Administration (US FDA) for CAR T cell therapy Breyanzi for the treatment of adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma. Breyanzi is a differentiated CAR T cell therapy made from a patient’s own T cells, which are collected and genetically reengineered to become CAR T cells that are then delivered via infusion as a one-time treatment.

The cell and gene therapy market report table of contents includes:
1. Executive Summary

2. Cell and Gene Therapy Market Characteristics
3. Cell and Gene Therapy Market Trends And Strategies
4. Cell and Gene Therapy Market – Macro Economic Scenario
5. Global Cell and Gene Therapy Market Size and Growth
   .
6. Global Cell and Gene Therapy Market Competitive Benchmarking
7. Global Cell and Gene Therapy Market Competitive Dashboard
8. Key Mergers And Acquisitions In The Cell and Gene Therapy Market
9. Cell and Gene Therapy Market Future Outlook and Potential Analysis
10. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model